[HTML][HTML] Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target
Y Wen, J Cai, Y Hou, Z Huang, Z Wang - Oncotarget, 2017 - ncbi.nlm.nih.gov
Y Wen, J Cai, Y Hou, Z Huang, Z Wang
Oncotarget, 2017•ncbi.nlm.nih.govEpigenetic modifications in cancer stem cells largely result in phenotypic and functional
heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste
homolog 2 (EZH2), the catalytic subunit of Polycomb repressor complex 2, is highly
expressed in cancer stem cells of numerous malignant tumors and has a critical function in
cancer stem cell expansion and maintenance. Here, we review up-to-date information
regarding EZH2 expression patterns, functions, and molecular mechanisms in cancer stem …
heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste
homolog 2 (EZH2), the catalytic subunit of Polycomb repressor complex 2, is highly
expressed in cancer stem cells of numerous malignant tumors and has a critical function in
cancer stem cell expansion and maintenance. Here, we review up-to-date information
regarding EZH2 expression patterns, functions, and molecular mechanisms in cancer stem …
Abstract
Epigenetic modifications in cancer stem cells largely result in phenotypic and functional heterogeneity in many solid tumors. Increasing evidence indicates that enhancer of zeste homolog 2 (EZH2), the catalytic subunit of Polycomb repressor complex 2, is highly expressed in cancer stem cells of numerous malignant tumors and has a critical function in cancer stem cell expansion and maintenance. Here, we review up-to-date information regarding EZH2 expression patterns, functions, and molecular mechanisms in cancer stem cells in various malignant tumors and discuss the therapeutic potential of targeting EZH2 in tumors.
ncbi.nlm.nih.gov